Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 5/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | GAA | P10253 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.39 |
| ▸ | ALPL | P05186 | 1/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2634893 | 0.87 | ALDH1A1 (0.45) | ALDH1A1SMN1; SMN2TSHRKMT2AGAA | |
| SCHEMBL2635599 | 0.86 | MEN1 (0.43) | ALDH1A1SMN1; SMN2TSHRKMT2AGAA | |
| SCHEMBL2635468 | 0.86 | MEN1 (0.46) | ALDH1A1TSHRKMT2AMEN1RAB9A | |
| SCHEMBL2635315 | 0.85 | EPHX2 (0.45) | ALDH1A1SMN1; SMN2TSHRKMT2AMEN1 | |
| SCHEMBL2635278 | 0.83 | EPHX2 (0.45) | ALDH1A1TSHRKMT2AMEN1RAB9A | |
| SCHEMBL2635557 | 0.83 | MEN1 (0.50) | ALDH1A1TSHRKMT2AMEN1RAB9A | |
| SCHEMBL2635628 | 0.82 | MEN1 (0.46) | ALDH1A1TSHRKMT2AMEN1RAB9A | |
| SCHEMBL2635794 | 0.81 | ALDH1A1 (0.49) | ALDH1A1TSHRKDM4EKMT2AGAA | |
| SCHEMBL2634767 | 0.80 | HTT (0.47) | SMN1; SMN2KDM4EKMT2AGAAMEN1 | |
| SCHEMBL2634867 | 0.79 | CYP3A4 (0.44) | ALDH1A1SMN1; SMN2TSHRKMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130109711-A1 | NOVEL COMPOUNDS | Convergence Pharmaceuticals Limited (GB) | 2013-05-02 | — | — | US | claimed |
| US-20130109711-A1 | NOVEL COMPOUNDS | Convergence Pharmaceuticals Limited (GB) | 2013-05-02 | — | — | US | disclosed |
| US-20130109711-A1 | NOVEL COMPOUNDS | Convergence Pharmaceuticals Limited (GB) | 2013-05-02 | — | — | US | disclosed |
| EP-2569317-A1 | SPIROCYCLIC DERIVATIVES WITH AFFINITY FOR CALCIUM CHANNELS | Convergence Pharmaceuticals Limited (GB) | 2013-03-20 | — | — | EP | disclosed |
| WO-2011141728-A1 | SPIROCYCLIC DERIVATIVES WITH AFFINITY FOR CALCIUM CHANNELS | Convergence Pharmaceuticals Limited (GB) | 2011-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109711-A1 | NOVEL COMPOUNDS | TRPV2, CACNA1C, CACNA1B | ALDH1A1 3342/4885SMN1; SMN2 826/4885TSHR 4127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.